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Cardiovascular diseases (CVDs) are the major cause of morbidity/mortality among breast cancer (BC) 
patients. Observation of the daily practice in eight experienced Polish oncology centers was conducted 
to find all possible predictors of new cases of heart failure (HF) and overall survival (OS) of metastatic 
BC patients treated with liposomal doxorubicin, taking into account the impact of pre‑existing CVDs. 
HF was the cause of premature discontinuation of liposomal doxorubicin therapy in 13 (3.2%) of 402 
patients. The probability of developing HF was higher in women with pre‑existing CVDs (HR 4.61; 
95%CI 1.38–15.38). Independent of CVDs history, a lower risk of HF was observed in those treated with 
a cumulative dose of liposomal doxorubicin > 300 mg/m2 (HR 0.14; 95% CI 0.04–0.54) and taxane‑
naive (HR 0.26; 95% CI 0.07–0.96). Multivariate analysis including the presence of pre‑existing CVDs 
and occurrence of new HF, revealed a liposomal doxorubicin in cumulative doses of > 300 mg/m2 as a 
beneficial predictor for OS (HR 0.61; 95% CI 0.47–0.78) independently of subsequent chemotherapy 
(HR 0.72; 95% CI 0.57–0.92) or endocrine therapy (HR 0.65; 95% CI 0.49–0.87). Higher doses of 
liposomal doxorubicin can decrease mortality in metastatic BC without increasing the risk of HF. The 
clinical benefit is achieved regardless of pre‑existing CVDs and subsequent anticancer therapy.
Patients with breast cancer (BC) are particularly vulnerable to the cardiotoxicity of antineoplastic treatment 
(hormone therapy, radiation, chemotherapy, anti-HER2 drugs) and therefore the (neo-) adjuvant treatment may 
have an impact on the later deterioration of cardiac function and overall performance  status1,2. Planning cancer 
treatments in patients with significant risk factors for developing heart failure (HF) is a major  problem3. It is 
also relatively difficult to treat elderly patients or those with cardiovascular diseases (CVDs), i.e. heart disease 
or at least  hypertension4,5.
Some patients with metastatic BC can live for many years and it is worth identifying clinical features that 
have an effect on survival. The prognosis and thus the choice of treatment can be influenced by many factors, 
like the hormone/HER2 receptor status, the effectiveness and toxicity of previous therapies, the patient’s bio-
logical age and comorbidities. Anthracycline or taxane-based regimens are one of the preferred therapies for 
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HER2-negative metastatic BC. Two liposomal forms of anthracyclines (pegylated and non-pegylated doxoru-
bicin) are perceived as less toxic for the heart. The European Society for Medical Oncology (ESMO) guidelines 
recommend the use of liposomal doxorubicin in patients previously treated (adjuvant or palliative therapy) 
with conventional anthracyclines or taxanes and who do not require complex chemotherapy (I/A). Based on 
this document, liposomal doxorubicin may also be an option in subsequent lines of anticancer treatment even 
in HER2-positive metastatic BC (II/A)6.
The presented study based on the daily practice of eight experienced Polish oncology centers has been under-
taken to check the real impact of liposomal doxorubicin on cardio-oncology prognoses of metastatic BC patients.. 
Two main purposes were defined.
• cardiology purpose identification of predictors of new-onset HF adjusted for the presence of pre-existing 
CVDs.
• oncology purpose assessment of how the administration of liposomal doxorubicin can influence overall sur-
vival (OS).
The final aim in the study was to assess OS in multivariate analysis including the history of pre-existing 
CVDs, the occurrence of new-onset HF,, patients’ demographic characteristics (age, obesity etc.), characteris-
tics of cancer disease as well as characteristics of therapy with liposomal doxorubicin, previous and subsequent 
anticancer therapy.
Results
Retrospective analysis covered 402 women with metastatic BC. Characteristics of histopathological diagnoses, 
localization of metastases and previous antitumor treatment are presented in detail in Table 1.
Most of the women had received conventional doxorubicin treatment in the past: the median dose was 
240 mg/m2, (interquartile range, IQ: 0–360 mg/m2). CVDs as well as their significant risk factors were frequent 
(Table 1). Among those studied, patients with metastatic BC and CVDs more often had concomitant diabetes, 
obesity, hypothyroidism and were older (≥ 60y). Although there were no differences in the histological type, 
the location of metastases and indications for adjuvant / neoadjuvant therapy, patients with a history of CVDs 
were more likely to avoid conventional anthracyclines at an earlier stage of cancer therapy 51/36.2% vs 68/26.1% 
(p = 0.03).
The median duration of active liposomal doxorubicin treatment was 106 days (3.5 months). The median total 
dose of liposomal doxorubicin of 300 mg/m2, (IQ:180–360 mg/m2) was given. The median number of cycles of 
liposomal doxorubicin was six.
Out of 402 patients, in 230 women (57.21%), the treatment was terminated due to cancer progression. Moreo-
ver, 46 women (11.44%) had the treatment withdrawn due to unacceptable toxicity: 20 women (4.98%) had a 
hematological toxicity, 14 women experienced cardiovascular complications (3.5%), including 13 cases of new-
onset HF with reduced ejection fraction (3.2%) and one case of acute pulmonary embolism (Table 1). In each 
case of HF, the left ventricular ejection fraction was significantly reduced, i.e. below 40% when their baseline 
level had been above 50%.
In addition to hematological and cardiac toxicity, 12 women (3%) were diagnosed with other serious toxic-
ity: general poor treatment tolerance (n = 4), significant deterioration of general condition and weakness (n = 3), 
hepatotoxicity (n = 2), acute infection (n = 1), unacceptable skin complications (n = 1), hypersensitivity reaction 
(n = 1).
The remaining 126 women (31.34%) completed liposomal doxorubicin treatment based on the decision of 
an independent oncologist. Each of these patients was under clinical observation to assess the onset of their 
cancer progression.
Factors predicting the occurrence of new-onset HF during active liposomal doxorubicin treatment were 
(Table 2): pre-existing CVDs HR 4.61 (95% CI 1.38–15.38, p = 0.01), previous treatment with taxanes HR 3.76 
(95% CI 1.03–13.73; p = 0.04) especially taxanes in a palliative setting HR 3.5 (95% CI 1.13–10.9; p = 0.03), 
and a cumulative dose of liposomal doxorubicin > 300 mg/m2: HR 0.16 (95% CI 0.04–0.6; p = 0.007). Previ-
ous conventional doxorubicin therapy in a palliative setting was of borderline significance (HR 3.23; 95% CI 
0.87–12.02; p = 0.08) even with a cumulative dose ≥ 400 mg/m2 (HR 4.26; 95% CI 0.91–19.79; p = 0.06). Regardless 
of CVDs history, a lower risk of HF was observed in patients treated with cumulative doses of liposomal doxoru-
bicin > 300 mg/m2 in comparison to others (HR 0.14; 95% CI 0.04–0.54; p = 0.004). A higher risk of new-onset 
HF was observed for patients after previous palliative chemotherapy with taxanes (HR 3.85; 95% CI 1.23–12.02; 
p = 0.02), or conventional doxorubicin (HR 3.48; 95% CI 0.93–12.95; p = 0.06) especially in doses ≥ 400 mg/m2 
(HR 4.07; 95% CI 0.88–18.93; p = 0.07).
The median of progression-free survival (PFS) was 150 days (5 months). During the observation 306 patients 
(76,1%) died. The median OS was 492 days (16.4 months). Factors significantly affecting OS were: ER or PR 
positive disease (HR 0.71; 95% CI 0.54–0.95; p = 0.02) or HER2 positive (HR 1.38; 95% CI 1.06–1.82; p = 0.02), 
metastases localization: liver (HR 1.33; 95% CI 1.06–1.66, p = 0.01) or central nervous system (HR 1.64; 95% CI 
1.15–2.35; p = 0.006), no neoadjuvant therapy (HR 0.65; 95% CI 0.5–0.83, p = 0.0007), doxorubicin and taxanes 
in neoadjuvant setting (HR 1.46; 95% CI 1.1–1.94; p = 0.008) as well as earlier palliative treatment with taxanes 
(HR 1.57; 95% CI 1.22–2.04; p = 0.0005), anti-HER2 (HR 1.5; 95% CI 1.02–2.2; p = 0.04) or endocrine therapy 
(HR 1.58; 95% CI 1.2–2.1; p = 0.001). Liposomal doxorubicin treatment had a positive effect on OS if the follow-
ing conditions were met: first line of palliative setting (HR 0.53; 95% CI 0.42–0.66; p < 0.000001), cumulative 
dose > 300 mg/m2 (HR 0.53; 95% CI 0.42–0.67; p < 0.000001), treatment duration > 3.5 months (HR 0.48; 95% 
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Patients with cardiovascular 
diseases
N = 141 (%)
Patients without cardiovascular 
diseases
N = 261 (%) p value
Clasical CV risk factors
Diabetes 20 (5.0) 18 (12.8) 2 (0.8)  < 0.0001
Obesity (BMI ≥ 30 kg/m2) 83 (20.6) 42 (29.8) 41 (15.7) 0.0009
Older age (≥ 60y) 185 (46) 91 (64.5) 94 (36)  < 0.000001
Hypothyroidism 17 (4.2) 11 (7.8) 6 (2.3) 0.009
Histopatological diagnosis
ER or PR positive 331 (82.3) 116 (82.3) 215 (82.4) 0.98
HER2 positive 77 (19.2) 32 (22.7) 45 (17.2) 0.18
Triple negative 48 (11.9) 13 (9.2) 35 (13.4) 0.22
Site of metastases
Pericardium / myocardium 4 (1) 2 (1.4) 2 (0.8) 0.92
Lung 135 (33.6) 56 (39.7) 79 (30.3) 0.056
Pleura 38 (9.5) 16 (11.3) 22 (8.4) 0.34
Liver 179 (44.5) 59 (41.8) 120 (46) 0.43
Bone 185 (46) 63 (44.7) 122 (46.7) 0.69
Nodules 98 (24.4) 39 (27.7) 59 (22.6) 0.26
Soft tissue or skin 45 (11.2) 21 (14.9) 24 (9.2) 0.08
Central nervous system 36 (9) 11 (7.8) 25 (9.6) 0.55
Peritoneal metastases 17 (4.2) 5 (3.5) 12 (4.6) 0.81
Ovary / uterus 12 (3) 5 (3.5) 7 (2.7) 0.86
Local progression 33 (8.2) 7 (5.0) 26 (10) 0.08
Previous adjuvant anticancer 
therapy
Radiotherapy: left-sided 101 (25.1) 32 (22.7) 69 (26.4) 0.41
Radiotherapy: right-sided 126 (31.3) 45 (31.9) 81 (31) 0.86
Doxorubicin in adjuvant setting 166 (41.3) 53 (37.6) 113 (43.3) 0.27
Taxanes in adjuvant setting 74 (18.4) 33 (23.4) 41 (15.8) 0.057
Anti-HER2 in adjuvant setting 19 (4.7) 10 (7.1) 9 (3.4) 0.1
Endocrine therapy in adjuvant 
setting 64 (15.9) 27 (19.1) 37 (14.2) 0.19
Previous neoadjuvant anticancer 
therapy
No neoadjuvant 305 (75.9) 113 (80.1) 192 (73.6) 0.14
Doxorubicin in neoadjuvant 
setting 96 (23.9) 28 (19.9) 68 (26.1) 0.16
Taxanes in neoadjuvant setting 68 (16.9) 17 (12.1) 51 (19.5) 0.056
Doxorubicin and Taxanes in neo-
adjuvant setting 67 (16.7) 17 (12.1) 50 (19.2) 0.068
Previous palliative anticancer 
therapy
Doxorubicin in palliative setting 46 (11.4) 15 (10.6) 31 (11.9) 0.71
Taxanes in palliative setting 97 (24.1) 31 (22) 66 (25.3) 0.46
Anti-HER2 in palliative setting 33 (8.2) 13 (9.2) 20 (7.7) 0.59
Endocrine therapy in palliative 
setting 74 (18.4) 29 (20.6) 45 (17.2) 0.41
Previous treatment with conven-
tional doxorubicin
Conventional doxorubicin 
dose ≥ 250 mg/m2 170 (42.3) 51 (36.2) 119 (45.6) 0.068
Conventional doxorubicin 
dose ≥ 400 mg/m2 26 (6.5) 6 (4.3) 20 (7.7) 0.18
Taxane-naive 190 (47.3) 70 (49.6) 120 (46) 0.48
Anthracycline—naive 119 (29.6) 51 (36.2) 68 (26.1) 0.03
Characteristics of therapy with 
liposomal doxorubicin
First line in palliative setting 234 (58.2) 82 (58.2) 152 (58.2) 0.99
Cumulative dose > 300 mg/m2 158 (39.3) 53 (37.6) 105 (40.2) 0.6
Monotherapy 82 (20.4) 28 (19.9) 54 (20.7) 0.84
Treatment time > 3.5 months 202 (50.2) 67 (47.5) 135 (51.7) 0.42
Treatment time ≤ 2 months 95 (23.6) 39 (27.7) 56 (21.5) 0.16
Cardiovascular events as end of 
treatment 14 (3.5) 8 (5.7) 6 (2.3) 0.078
Heart failure as end of treatment 13 (3.2) 8 (5.7) 5 (1.9) 0.08
Hematological toxicity as end of 
treatment 20 (5) 6 (4.3) 14 (5.4) 0.63
Other toxicity as end of treatment 12 (3) 8 (5.7) 4 (1.5) 0.04
PFS > 5 months 196 (48.8) 64 (45.4) 132 (50.6) 0.32
Subsequent anticancer therapy
Cytostatics 189 (47.1) 68 (48.2) 121 (46.4) 0.72
Taxanes 93 (23.1) 27 (19.1) 66 (25.3) 0.18
Endocrine therapy 129 (32.1) 47 (33.3) 82 (31.4) 0.69
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CI 0.38–0.61; p < 0.000001). Patient’s characteristics with longer OS included being taxane-naive (HR 0.57; 95% 
CI 0.46–0.72; p = 0.000002) and anthracycline-naive (HR 0.63; 95% CI 0.48–0.81; p = 0.0004).
In Table 3, the key cardio-oncology predictors of OS were presented in multivariate analysis. Independent of 
the presence of pre-existing CVDs and occurrence of HF: liposomal doxorubicin in cumulative dose > 300 mg/
m2 (HR 0.61; 95% CI 0.47–0.78; p = 0.0001), subsequent chemotherapy (HR 0.72; 95% CI 0.57–0.92; p = 0.008) 
or endocrine therapy (HR 0.65; 95% CI 0.49–0.87; p = 0.003) were confirmed as significant and positive. There 
was borderline significance from previous conventional doxorubicin doses ≥ 250 mg/m2 (HR 0.75; 95% CI 
0.56–1.00; p = 0.05).
Discussion
Metastatic BC remains a disease with an unfavorable prognosis, in which the median survival is about 3 years 
and only 25% of patients survive 5 years7,8. The problem is its heterogeneity, incomprehensible mechanisms of 
resistance to various therapies and the lack of predictive factors in many clinical situations. An additional issue 
is the coexistence of significant chronic comorbidities such as  CVDs9. In our study, patients with a history of 
CVDs, despite the higher risk of developing HF, did not have shorter OS rates. We believe, that thanks to the 
guideline-guided treatment of HF with reduced ejection fraction, our patients did not die prematurely. The 
recognized new HF episodes did not affect the benefits of liposomal doxorubicin treatment.
A large percentage of women with breast cancer experience a relapse after radical treatment. In an era when 
anthracyclines and taxanes are widely used in adjuvant treatment, the choice of optimal treatment for metastatic 
BC takes on a new dimension especially with respect to anthracycline  reuse10–12. In terms of cardiac safety, it 
seems justified to use liposomal doxorubicin after previous adjuvant treatment in its conventional  form13–15. 
However, analysis of four prospective studies on pegylated liposomal doxorubicin in metastatic BC showed that 
taxane naïve patients or those with a better ECOG functional class have the greatest clinical benefit and thus 
significantly longer survival  rates16. The previous dose of conventional anthracyclines, however, was of little 
 importance17. The univariate analysis of our study confirms these regularities: the greatest benefit for survival 
is obtained by patients without prior treatment with taxanes or anthracyclines. On the other hand, it should be 
admitted that the previous use of conventional doxorubicin in doses ≥ 250 mg/m2 may have positive significance 
for OS, which was observed in multivariate analysis of 18 cardio-oncology predictors. Furthermore, surpris-
ingly, in univariate analysis adjusted for the presence of CVDs, previous conventional anthracyclines treatment 




Analysis adjusted for 
presence of CVDs
HR 95%CI p value HR 95%CI p-value
Patients with cardiovascular diseases (CVDs) vs patients without CVDs 4.61 1.38–15.38 0.01 – – –
Older age (≥ 60y vs < 60y) 1.16 0.37–3.6 0.8 – – –
Histopatological diagnosis
ER or PR positive 1.82 0.23–14.25 0.57 – – –
HER2 positive 1.05 0.29–3.84 0.94 – – –
Triple negative 0.9 0.11–7.02 0.92 – – –
Previous adjuvant anticancer therapy
Radiotherapy: left-sided 0.54 0.12–2.43 0.42 – – –
Radiotherapy: right-sided 1.27 0.4–3.98 0.68 – – –
Doxorubicin in adjuvant setting 0.88 0.28–2.8 0.83 – – –
Taxanes in adjuvant setting 1.23 0.34–4.5 0.75 – – –
Anti-HER2 in adjuvant setting 0.91 0.11–7.56 0.93 – – –
Endocrine therapy in adjuvant setting 0.45 0.06–3.52 0.45 – – –
Previous neoadjuvant anticancer therapy
Doxorubicin in neoadjuvant setting 1.44 0.39–5.38 0.58 – – –
Taxanes in neoadjuvant setting 1.35 0.29–6.22 0.7 – – –
Previous palliative anticancer therapy
Doxorubicin in palliative setting 3.23 0.87–12.02 0.08 3.48 0.93–12.95 0.06
Taxanes in palliative setting 3.5 1.13–10.9 0.03 3.85 1.23–12.02 0.02
Anti-HER2 in palliative setting 1.17 0.15–9.08 0.88 – – –
Endocrine therapy in palliative setting 2.3 0.69–7.67 0.17 – – –
Previous treatment with conventional doxorubicin
Conventional doxorubicin dose ≥ 250 mg/m2 
vs < 250 mg/m2 1.58 0.53–4.71 0.41 – – –
Conventional doxorubicin dose ≥ 400 mg/m2 
vs < 400 mg/m2 4.26 0.91–19.79 0.06 4.07 0.88–18.93 0.07
Taxane-naive vs pretreated with taxanes 0.27 0.07–0.97 0.04 0.26 0.07–0.96 0.04
Anthracycline—naive vs pretreated with anthracyclines 0.69 0.19–2.57 0.58 – – –
Characteristics of therapy with liposomal doxorubicin
First vs next line of palliative setting 0.68 0.22–2.12 0.51 – – –
Cumulative dose > 300 mg/m2 vs ≤ 300 mg/m2 0.16 0.04–0.6 0.007 0.14 0.04–0.54 0.004
Monotherapy vs combination with cyclophosphamide 1.16 0.35–3.85 0.8 – – –
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even in high doses (≥ 400 mg/m2) was of borderline relevance to the risk of HF development during liposomal 
doxorubicin therapy, while taxanes were of greater importance.
In a scientific discussion, the use of liposomal doxorubicin as maintenance therapy was also considered. While 
this is not possible with conventional doxorubicin due to the risk of cumulative dose-dependent cardiotoxicity, 
with liposomal doxorubicin this problem is significantly  reduced18. Our observations indirectly confirm this 
possibility, especially since longer OS was obtained at higher doses of liposomal doxorubicin (above 300 mg/
m2) and when this treatment lasted longer than 3.5 months. However, further research is needed to determine 
the optimal duration of such therapy and optimal dosing of liposomal doxorubicin per cycle.
There are a number of common risk factors for developing both BC and CVDs, including diabetes, hyperten-
sion, hyperlipidemia, and  obesity19,20. Compared to the general population, breast cancer patients also have an 
increased cardiovascular mortality, this risk is about twice as high when considering age, menopausal status and 
other classic risk  factors21. Recent data suggest that women with a history of coronary artery disease, hyperten-
sion or diabetes have a significantly increased risk of cardiovascular complications during both adjuvant and 
palliative treatment for  BC22. Polish data indicate that the occurrence of HF in patients with metastatic BC is a 
consequence of previous (neo) adjuvant chemotherapy with anthracyclines and a history of coronary  events23. It 
becomes clear that the increased cardiovascular morbidity in women with BC is due to the frequent occurrence 
of adverse classic risk factors that are often not optimally controlled (e.g. smoking, low physical activity, high 
BMI, lipid disorders) and adverse effects of cancer  treatment24,25. Left breast radiotherapy compared to right 
breast radiotherapy is also associated with a higher risk of cardiovascular death as well as death from myocardial 
 infarct26. The risk of cardiovascular death is higher after anthracycline treatment for breast cancer if women had 
other risk factors such as diabetes or  hypertension27,28. Interestingly, in our study main classic risk factors like 
obesity (with probably insulin resistance) or older age were more common in patients with CVDs, but they were 
not associated with higher risk of mortality in univariate and multivariate analysis.
The cumulative dose is the strongest risk factor for anthracycline  cardiotoxicity29. The risk increases with the 
administered dose, but there is no safe dose of anthracyclines. Everything depends on one’s individual predisposi-
tion. Cardiovascular events and symptomatic HF were observed at lower doses (< 400 mg/m2) especially among 
patients with cardiovascular risk  factors30. Elderly patients with concomitant heart or vascular diseases and those 
receiving other cytostatics with synergistic cardiotoxicity potential are at greatest risk. An important finding of 
our Polish study is the lack of influence of high cumulative doses of liposomal doxorubicin on the occurrence 
of HF. Interestingly, we confirmed the importance of other anti-cancer drugs, primarily widely used taxanes. In 
our opinion, accurate cardiological screening of patients receiving taxanes is needed, especially if patients have 
a history of concomitant CVDs. Anthracyclines are avoided in these patients, but taxanes are widely used, which 
is also confirmed by our Polish observations.
The mission of cardio-oncology should be a full personalization of the treatment, i.e. a collective, simultane-
ous look at both cardiological and oncological problems, which can be the cause of either premature death or 
worsening of a patient’s quality of life. A special and rare challenge of cardio-oncology is the treatment of diseases 
when cancer directly involves the structure of the cardiovascular  system31,32. A more frequent task of cardio-
oncology is an antitumor treatment of patients with a history of CVDs or those experiencing new iatrogenic 
cardiovascular complications during oncological  treatment33,34. It is suggested that HF induced by conventional 
anthracycline therapy is associated with a risk of increased  mortality35,36. Our Polish research confirms the 
Table 3.  The selected cardio-oncology predictors of overall survival.
Evaluated factors
Univariate analysis Multivariate analysis
HR 95%CI p value HR 95%CI p value
Patients with pre-existing cardiovascular diseases (CVDs) vs patients without CVDs 0.999 0.79–1.27 0.996 0.998 0.77–1.29 0,99
Patients with heart failure as end of treatment with liposomal doxorubicin vs patients without this complication 1.31 0.73–2.33 0.36 1.08 0.59–1.98 0.8
Older age (≥ 60y vs < 60y) 1.04 0.83–1.30 0.76 1.19 0.93–1.53 0.17
Obesity (BMI ≥ 30 kg/m2 vs < 30 kg/m2) 0.76 0.57–1.01 0.054 0.85 0.63–1.14 0.28
Prognostically unbeneficial site of metastases
Central nervous system vs other sites 1.64 1.15–2.35 0.006 1.5 1.02–2.18 0.04
Liver vs other sites 1.33 1.06–1.66 0.01 1.43 1.12–1.83 0.004
Pericardium / myocardium vs other sites 2.25 0.83–6.06 0.11 2.06 0.74–5.76 0.17
Histopatological diagnosis of breast cancer
HER2 positive vs other diagnosis 1.38 1.06–1.82 0.02 1.28 0.95–1.73 0.11
Triple negative vs other diagnosis 1.28 0.92–1.79 0.14 1.15 0.8–1.66 0.45
Taxane-naive vs pretreated with taxanes 0.57 0.46–0.72 0.000002 0.8 0.59–1.07 0.14
Anthracycline—naive vs pretreated with anthracyclines 0.63 0.48–0.81 0.0004 0.79 0.55–1.14 0.21
Patients after left-sided radiotherapy vs others 1.27 0.99–1.64 0.06 1.02 0.78–1.33 0.9
Patients treated earlier with conventional doxorubicin dose ≥ 250 mg/m2 vs others 1.17 0.93–1.46 0.18 0.75 0.56–1.00 0.05
Characteristics of therapy with liposomal doxorubicin
First vs next line ofpalliative setting 0.53 0.42–0.66  < 0.000001 0.82 0.61–1.11 0.2
Monotherapy vs combination with cyclophosphamide 1.31 0.996–1.74 0.05 1.01 0.74–1.39 0.9
Cumulative dose > 300 mg/m2 vs ≤ 300 mg/m2 0.53 0.42–0.67  < 0.000001 0.61 0.47–0.78 0.0001
Subsequent anticancer therapy
Patients treated with cytostatics vs others 0.96 0.77–1.2 0.71 0.72 0.57–0.92 0.008
Patients treated with endocrine therapy vs others 0.56 0.44–0.72 0.000007 0.65 0.49–0.87 0.003
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successful use of liposomal doxorubicin even in patients with metastases to myocardium/pericardium or after 
previous therapy with conventional doxorubicin. This study demonstrates that the new cases of HF induced by 
liposomal doxorubicin were not associated with a significant increase in mortality.
The optimal cardiovascular protection in oncology that the cardiologist can use is a debatable  issue37. There 
are trials confirming or contradicting the role of beta-blockers and inhibitors of the renin–angiotensin–aldos-
terone system (RAAS) in the prevention of primary anthracycline cardiotoxicity, especially in patients without 
classic risk factors for HF. On the other hand, it should be stated that people treated with beta-blockers or RAAS 
inhibitors due to CVDs are more likely to experience  HF38. This is undoubtedly a consequence of the main risk 
factor in this case being hypertension or coronary artery disease, treated with a beta-blocker or RAAS inhibi-
tors. Our study confirmed CVDs as the main predictors for the development of HF even in patients treated with 
liposomal doxorubicin.
Various prevention strategies are undertaken in the field of clinical  oncology39. The calculation of the cumula-
tive anthracycline dose seems to be a special  concern40. It has been confirmed that higher cumulative doses of 
liposomal doxorubicin (pegylated or nonpegylated) are associated with a significantly lower risk of cardiotoxicity 
in comparison to conventional anthracyclines (OR = 0.18; 95% CI, 0.08–0.38)41. Both liposomal forms are avail-
able in the treatment of metastatic BC, and they are considered as effective as conventional doxorubicin, and 
definitely safer for the  heart42. Observations of the Polish Lymphoma Research Group show that it is possible to 
use liposomal doxorubicin safely and beneficially for the course of treatment in patients with co-existing  CVDs43. 
Although we treat older and more cardiologically ill patients, thanks to the use of liposomal doxorubicin the 
prognosis can be even  better44.
The American Society of Clinical Oncology (ASCO)45 indicates the use of liposomal forms of doxorubicin in 
patients who are to receive high doses of anthracyclines (e.g. doxorubicin ≥ 250 mg / m2) as one of the preventive 
strategies for reducing the risk of cardiovascular complications. The European Society of Cardiology (ESC) in its 
position paper on the toxic effect of oncological treatment on the cardiovascular  system46 confirms that statement. 
The document also emphasizes that choosing liposomal doxorubicin maintains efficacy comparable to conven-
tional anthracycline. Our Polish results from daily practice support clearly these opinions from ASCO and ESC.
Our study has several limitations. First, its retrospective design may lead to data inconsistency. There was 
insufficient control over the principles of the initially used cardiac treatment for CVDs. Secondly, we analyzed 
a heterogenic population of metastatic BC patients (e.g. receptor status, number of metastatic sites etc.). In 
addition, there were substantial differences in previous and subsequent treatment lines. This could have had an 
important impact on survival statistics. Thirdly, patients were receiving one of two liposomal doxorubicin forms 
understood as comparable. Despite these limitations, to our knowledge, this study is the world’s largest summary 
of clinical experience with liposomal doxorubicin treatment regarding predictors of new-onset heart failure 
and overall survival in metastatic BC patients. We can conclude that in patients with metastatic BC, prolonged 
liposomal doxorubicin treatment, i.e. lasting more than 3.5 months, and thus the administration of a higher 
cumulative dose, i.e. above 300 mg/m2, significantly increases OS. Although ESMO guidelines recommend the 
administration of liposomal doxorubicin after taxane or conventional anthracycline therapy, our univariate 
analysis demonstrates that the longest OS can be seen in patients who had not previously received these drugs. 
However, it should be noted that, prior treatment involving conventional doxorubicin does not shorten OS. The 
greatest benefit may be achieved among patients with positive hormone receptors, when subsequent therapy 
was possible and effective independent of pre-existing CVDs and new HF. However, BC patients triple negative 
or HER2 positive did not have worse OS based on the multivariate analysis of 18 cardio-oncology predictors.
Concomitant CVDs are obviously associated with a higher risk of the occurrence of HF during liposomal 
doxorubicin treatment and should also be carefully evaluated in this  population47. Notwithstanding this, patients 
with metastatic BC and concomitant CVDs may not have a worse prognosis, because newly diagnosed HF does 
not have to increase the overall mortality. It is worth considering that the earlier therapy with taxanes is a risk 
factor for developing HF.
Further research is needed to define a better clinical position for liposomal anthracyclines.
Methods
The study provides a retrospective summary of data on metastatic BC treatment in eight Polish oncology cent-
ers: the beginning of therapy in the period from March 2008 to September 2018 (10.5 years), with the closing of 
follow-up in August 2019. In each case an oncologist independently recognized that the metastatic BC patient 
should benefit from liposomal doxorubicin treatment and qualified for this therapy for three important reasons: 
(1) the predicted high efficacy of doxorubicin in metastatic BC; (2) co-existing cardiovascular diseases (CVDs); 
(3) previous treatment with conventional anthracyclines. Two liposomal forms of doxorubicin are available 
in Europe for metastatic BC: (1) pegylated liposomal doxorubicin indicated as a monotherapy in patients at 
increased risk of cardiac complications, (2) non-pegylated liposomal doxorubicin indicated as first-line treat-
ment, used in combination with cyclophosphamide.
In the analysis of the risk of HF and cardio-oncology predictors of mortality as the primary goal, the follow-
ing factors were taken into account:
• medical history, including pre-existing CVDs, metabolic diseases such as diabetes and obesity and unmodifi-
able risk factors such as age and gender,
• hormone/HER2 receptor status, metastasis location,
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• duration and cumulative dose of liposomal doxorubicin, observed toxicity including cardiovascular and 
hematological complications, obtained progression-free survival time (PFS)
• subsequent anticancer therapy lines after liposomal doxorubicin.
The study was performed in accordance with the local bioethics committee guidelines. Pre-existing CVDs 
should be confirmed earlier by independent certified cardiologists and treated according to  guidelines48. Patients 
received angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) due to 
arterial hypertension. Statins were used for hypercholesterolemia management. Beta-blockers were continued 
because of earlier recognized coronary artery disease or arrhythmias. Exclusion criteria were defined as: all types 
of heart failure previously recognized, even with preserved ejection fraction (EF), all types of asymptomatic 
left ventricular dysfunction with ejection fraction below 50%, and each hemodynamicly important heart valve 
disease. Patients with breast cancer metastases to pericardium or myocardium could be included.
In our hypothesis HF with reduced ejection fraction below 40% may be the real reason for terminating cancer 
therapy and can have a significant impact on the overall survival of patients with metastatic  BC49. The defini-
tion of HF with reduced ejection fraction proposed by the European Society of Cardiology was adopted in the 
 study50. In each case of such HF the appropriate guideline-guided treatment was used, including beta-blockers, 
RAAS inhibitors etc.
Statistical analysis was performed by Statistica (StatSoft), nominal parameters were presented as a percent-
age frequency, comparisons between groups with and without CVDs were made using the chi^2 test with Yates 
correction if indicated. Survival curves and Cox proportional hazard model were used to determine predictors 
for the occurrence of HF during active liposomal doxorubicin treatment in univariate analysis, then the most 
significant results were adjusted for the presence of CVDs. Correlations between selected cardio-oncology vari-
ables and mortality risk were performed in the univariate and multivariate Cox proportional hazard analysis. 
The results of the Cox models were presented as hazard ratios and 95% confidence interval (CI), a p value of less 
than 0.05 was considered significant.
Ethical approval. The protocol of the study was approved by Bioethical Committees at the Centre of Post-
graduate Medical Education in Poland (Resolution Number 16/PB/2020) and was in accordance with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent. Written informed consent of the treatment with liposomal doxorubicin was obtained 
from all patients.
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